Determining Value
OHE’s AMR consultation response
21 November 2023
This blog summarises our perspective on the recent proposals set out by NHS England to assess the value of new antibiotics via a new scoring system linked to a volume-delinked revenue guarantee payment. Key arguments outlined here were submitted to NHS England as part of OHE’s response to the consultation on proposals.
The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
12 October 2022
This second blog focuses on the value assessment used within the NICE-NHS England AMR pilot, which is crucial for capturing an antibiotic’s value so the subscription model can reward those with higher value.
The Value of Vaccines in Maintaining Health System Capacity in England
1 October 2021
This report has now been published as an article in Value in Health available here. The NHS is facing unprecedented health system pressure, with a record number…
Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making
1 September 2021
By placing a strain on health care systems and the global economy, the COVID-19 pandemic clearly shows the need to more comprehensively understand both supply- and…
Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
1 February 2021
The COVID-19 pandemic has revealed the broad and devastating health, economic and societal impact of a highly infectious and deadly disease. In addition to the human…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA,…
Ten Years of the NIHR: Achievements and Challenges for the Next Decade
1 June 2017
The National Institute for Health Research (NIHR), created in April 2006, is a “virtual” organisation often referred to as the research arm of the NHS. It…
Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
1 April 2017
The 2016 meeting of the HTAi Asia Policy Forum meeting was held in Kuala Lumpur, 17th -18th November 2016. The topic of the meeting was: Assessing…
Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
12 January 2014
This OHE Occasional Paper by Adrian Towse discusses Professor Bengt Jönsson’s observations in a 2011 publication about the role of relative effectiveness research (RE) in the…